SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is currently experiencing intense community volatility as the price tests the psychological one-dollar support level, fueling a heated divide between long-term holders betting on institutional utility and bears anticipating a deeper correction. Market participants are laser-focused on upcoming regulatory milestones and the potential for a liquidity shakeout, as investors weigh the balance between long-term fundamentals and immediate technical downside risks.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is capturing significant attention following a massive 20-year, $9.1 billion data center deal with Anthropic that underscores the company's aggressive pivot toward AI infrastructure. While the community is actively debating the stock's potential for long-term growth as a data center player, sentiment remains divided due to concerns over high volatility, potential share dilution to fund these projects, and frustration with recent price action that has seen overnight gains quickly fade.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing heightened market volatility as investors weigh the potential for a transformative data readout against concerns over a recent mixed shelf offering and the clinical performance of sonelokimab in psoriatic arthritis. The community is actively debating the timing of clinical updates and the company's long-term commercial value, with many bulls maintaining conviction in the drug's safety profile and pending BLA submission despite recent downward pressure.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is experiencing significant downward pressure as investors react to a broader food safety investigation involving a common produce supplier, despite the company confirming no direct link to the recent outbreak. The community remains heavily divided between long-term investors viewing the volatility as an attractive buying opportunity and traders skeptical of the stock's ability to maintain upward momentum.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors digest a large-scale share offering alongside massive demand for its AI data center power infrastructure, including recent turbine contracts with Siemens Energy. The community is actively debating the company's long-term growth potential and massive project backlog, with many bullish on its role in the AI power boom while others express frustration over institutional volatility and recent price action.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the stock represents a deep-value recovery play or a broken fundamental story amid ongoing struggles with market share in China and competition from niche brands. Community sentiment remains polarized, with many traders actively accumulating shares during price weakness while others express significant frustration over the stock's prolonged downtrend and underwhelming performance relative to the broader market.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav shares are experiencing significant volatility following reports of a potential legislative rider in a House appropriations bill that seeks to restrict the FCC from reconfiguring the 900 MHz band. While investors and institutional analysts remain focused on the long-term potential of the spectrum and the imminent regulatory path for an NPRM, the community is actively debating the political headwinds and the potential impact of this legislative maneuver.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following positive Phase 3 clinical trial results for its depression treatment, triggering a surge in investor interest and trading volume. The community is actively debating the stock's future valuation and the potential for a larger pharmaceutical acquisition, while navigating the impact of a newly announced large-scale equity offering.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is trending as investors focus on the company's strategic pivot toward AI infrastructure following its acquisition of Northern Data, a move that has significantly expanded its GPU capacity and data center footprint. The community is actively debating the potential for a massive short squeeze due to record-high short interest, while simultaneously analyzing upcoming earnings and formal guidance as key catalysts for a long-term valuation re-rating.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding shares are under intense pressure as a lower-than-expected revenue outlook and guidance have triggered a sharp sell-off, despite the company posting solid profit beats and margin expansion. The community is actively debating whether this pullback represents an attractive buying opportunity for a growth-oriented brand or a sign that the company is struggling to maintain its premium trajectory in a challenging consumer environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million.
Prelude Therapeutics (NASDAQ:PRLD) shares movedread more...

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) has earned an average rating of 'Hold' from the five brokerages that are presently covering the stock, Marketbeat.com reports. One...

Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital initiated coverage on shares of Prelude Therapeutics in a research note on Monday. They set a 'buy' rating and a $9.00 price target on the stock...

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research

Zacks Research raised Prelude Therapeutics to a "hold" rating in a research report on Tuesday...

Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday

Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-prelude-therapeutics-incorporated-stock...

HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price

HC Wainwright upped their price objective on shares of Prelude Therapeutics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Monday...

Insider Buying: Prelude Therapeutics (NASDAQ:PRLD) Director Acquires 2,815,315 Shares of Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) Director Orbimed Advisors Llc acquired 2,815,315 shares of the business's stock in a transaction on Tuesday, April 21st. The shares...

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Prelude Therapeutics Inc

Why Did PRLD Stock Surge 13% Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.14	--	--	N/A
Q2 '26	-$0.20	-$0.14	28.81%	BEAT
Q1 '26	-$0.25	-$0.13	48.51%	BEAT
Q4 '25	-$0.03	-$0.20	-566.67%	MISSED
Q3 '25	-$0.37	-$0.26	29.73%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings